17
Participants
Start Date
September 30, 2016
Primary Completion Date
July 24, 2018
Study Completion Date
July 24, 2018
Riociguat
riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
Placebo
Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
Hospital of Special Surgery (HSS), New York
University of Pittsburgh, Pittsburgh
Georgetown University, Washington D.C.
University of Michigan, Ann Arbor
University of Utah, Salt Lake City
Collaborators (1)
Bayer
INDUSTRY
Dinesh Khanna, MD, MS
OTHER